Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Alpha Tau Medical Ltd ( (DRTS) ) is now available.
On May 19, 2025, Alpha Tau Medical Ltd. announced its first quarter financial results and provided a corporate update, highlighting significant advancements in its clinical trials and regulatory approvals. The company reported impressive interim results from trials using Alpha DaRT in treating pancreatic cancer and head and neck squamous cell carcinoma, with high disease control and response rates. Notably, the FDA approved multiple Investigational Device Exemptions for U.S. pilot studies, and the company achieved MDSAP certification for its Jerusalem facility. Alpha Tau also completed a $36.9 million financing round, strengthening its capital position to support ongoing expansion efforts.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. operates in the medical technology industry, focusing on innovative cancer therapies. The company’s primary product, Alpha DaRT, is a breakthrough alpha-radiation therapy designed to treat solid tumors. Alpha Tau is committed to expanding its clinical trials and manufacturing capabilities, with a market focus on the U.S. and international regulatory compliance.
Average Trading Volume: 44,163
Technical Sentiment Signal: Hold
Current Market Cap: $235.7M
Find detailed analytics on DRTS stock on TipRanks’ Stock Analysis page.